Background/Aim: Germline BRCA1/2 mutations (gBRCA1/2m) confer a markedly increased lifetime risk of breast cancer. Although diverse second-hit mechanisms lead to biallelic inactivation of BRCA1/2, their relationship with the immune microenvironment remains poorly understood, particularly in Japanese populations. Patien...
Yukino Kawamura, K. Mori, F. Takeuchi et al.· Anticancer Research· 0 citations
The results highlight the antitumor activity and manageable safety profile of E7389-LF, indicating the potential of E7389-LF as a 1L treatment for patients with HER2-negative breast cancer, warranting further study.
Hiroshi Ishiguro, Y. Miyoshi, H. Yasojima et al.· Breast Cancer Research· 0 citations
Background Metastatic breast cancer (MBC) remains a treatable, but incurable disease. Anti-cancer treatments and supportive therapies aim to control disease, prolong survival, ameliorate physical symptoms and improve quality of life (QoL). Currently, no validated MBC-specific patient-reported outcome measures exist, an...
C. Bedding, K. Absolom, K. Pogoda et al.· Breast· 0 citations
Current evidence and ongoing studies on treatment de-escalation across breast cancer subtypes are summarized and integration of molecular biomarkers with response-adapted strategies may further refine risk stratification and support personalized treatment approaches.
M. Ono, Y. Sagara, Toshiyuki Ishiba et al.· Japanese Journal of Clinical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.